Results 241 to 250 of about 90,478 (344)

Adjuvant chemotherapy for gallbladder cancer: Current evidence, controversies, and future directions. [PDF]

World J Gastrointest Surg
Dai JW, Xing YX, Sun NZ.
europepmc   +1 more source

Life's Essential 8 and the Risk of Overall and Specific‐Site Cancer Types: A Large‐Scale Prospective Cohort Study

Cancer Medicine, Volume 15, Issue 1, January 2026.
ABSTRACT Background The Life's Essential 8 (LE8) framework, designed to prevent cardiovascular disease, is also linked to cancer risk, but the direct association between LE8 adherence and cancer incidence remains underexplored. Each LE8 component may affect cancer risk differently across organ systems, warranting further investigation into these ...
Li Deng, Xiao‐Meng Hao, Zhe Shu, Tong Liu, Qing‐Song Zhang, Hong‐Tao Wang, Han‐Ping Shi   +6 more
wiley   +1 more source

Identification of differentially expressed genes and associated immune cell types in South African gallbladder cancer patients. [PDF]

Sci Rep
Devar J, Baichan P, Mpangase PT, Elebo N, Candy GP, Smith M, Nweke EE.   +6 more
europepmc   +1 more source

Supplementary Table 1 from Chronic Exposure to Drinking Water Arsenic and Gallbladder Cancer Risk: Preliminary Evidence from Endemic Regions of India

Krithiga Shridhar, Manigreeva Krishnatreya, Soumyajit Sarkar, Ranjit Kumar, Dimple Kondal, Steena Kuriakose, Vinutha RS, Amulya K. Singh, Amal Chandra Kataki, Ashok Ghosh, Abhijit Mukherjee, Dorairaj Prabhakaran, Debapriya Mondal, Poornima Prabhakaran, Preet K. Dhillon   +14 more
openalex   +1 more source

Total Right Hepatic Labectomy for Cancer of the Gallbladder

, 1955
George T. Pack, Theodore R. Miller, Richard D. Brasfield   +2 more
openalex   +2 more sources

Primary Chest Wall Ewing Sarcoma With Diaphragmatic Invasion in an Adult: En‐Bloc Resection and Polypropylene Mesh Reconstruction

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Chest‐wall Ewing sarcoma (CWES) is uncommon in adults and often abuts vital thoracic structures, making R0 resection challenging despite gains with multimodal therapy. A 46‐year‐old Arab male presented with year‐long right‐sided chest pain, weight loss, and a firm mass over the lower right ribs.
Mohammad Alaa Aldakak, Ahmad Al‐Bitar, Raneem Ahmad, Hamza Alhallaq, Kinda Assoud, Hussain Chaban   +5 more
wiley   +1 more source

Multidimensional Assessment of Neurological Adverse Reactions Related to PD‐1 Inhibitors: A Real‐World Pharmacovigilance Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
This pharmacovigilance study systematically analyzed PD‐1 inhibitor–associated neurological adverse events using FAERS data from 2014 to 2024. Central nervous system toxicities, including encephalitis and brainstem encephalitis, were most prominent. Older age, female sex, specific cancer types, and combination therapies increased the risk, with most ...
Xiaofeng Hu, Xiaoli Wang, Bufu Tang, Dehuan Zhang, Rongbing Cai, Hui Jiang, Yaling Lin, Yiheng Song, Yiou Wang, Hairuo Huang, Dandan Guo, Xubin Sun, Hongjie Fan   +12 more
wiley   +1 more source

Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair. [PDF]

J Exp Clin Cancer Res
Ni X, Li M, Qiu W, Han J, Yu M, Zhang S, Zheng B, He J, Liu H.   +8 more
europepmc   +1 more source

Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial

Clinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.
Abstract Intestinal failure‐associated liver disease occurs in 20% to 30% of patients with short bowel syndrome and intestinal failure (SBS‐IF). Apraglutide is a glucagon‐like peptide‐2 (GLP‐2) analog in clinical development for the treatment of patients with SBS‐IF.
Gerard Greig, Justin Hay, Patricia Valencia, Mena Boules, Tomasz Masior   +4 more
wiley   +1 more source

Changing patterns of cholangiocarcinoma and gallbladder cancer: A regional perspective from Northeastern Italy. [PDF]

World J Gastrointest Oncol
Kirkik D, Ozabaci AN, Kalkanli Tas S.
europepmc   +1 more source